{
  "url": "https://voxday.net/2021/03/25/unlikely-to-end-well/",
  "scraped_at": "2025-12-21T22:42:19.132676",
  "title": "Unlikely to end well",
  "date_display": "March 25, 2021",
  "date_iso": "2021-03-25T17:22:55+00:00",
  "date_from_url": "2021-03-25",
  "author": "VD",
  "content_html": "<div class=\"entry-content\"><p><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335060/\" rel=\"noopener\" target=\"_blank\">The experimental results</a> of the pre-Covid not-vaccines do not suggest positive long-term results for the current not-vaccines:</p><blockquote><p>Design</p><p>Four candidate vaccines for humans with or without alum adjuvant were evaluated in a mouse model of SARS, a VLP vaccine, the vaccine given to ferrets and NHP, another whole virus vaccine and an rDNA-produced S protein. Balb/c or C57BL/6 mice were vaccinated IM on day 0 and 28 and sacrificed for serum antibody measurements or challenged with live virus on day 56. On day 58, challenged mice were sacrificed and lungs obtained for virus and histopathology.</p><p>Results</p><p>All vaccines induced serum neutralizing antibody with increasing dosages and/or alum significantly increasing responses. Significant reductions of SARS-CoV two days after challenge was seen for all vaccines and prior live SARS-CoV. All mice exhibited histopathologic changes in lungs two days after challenge including all animals vaccinated (Balb/C and C57BL/6) or given live virus, influenza vaccine, or PBS suggesting infection occurred in all. Histopathology seen in animals given one of the SARS-CoV vaccines was uniformly a Th2-type immunopathology with prominent eosinophil infiltration, confirmed with special eosinophil stains. The pathologic changes seen in all control groups lacked the eosinophil prominence.</p><p>Conclusions</p><p>These SARS-CoV vaccines all induced antibody and protection against infection with SARS-CoV. However, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components was induced. Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated.</p></blockquote><p>Translation: the not-vaccines successfully reduced symptoms and increased antibodies, just as the Covid not-vaccine has. The problem is that they also made the subjects hypersensitive to future SARS infections, which would explain the anomalous Israeli results and suggests that a considerably more lethal pandemic is in the cards.</p></div>",
  "content_text": "The experimental results\nof the pre-Covid not-vaccines do not suggest positive long-term results for the current not-vaccines:\nDesign\nFour candidate vaccines for humans with or without alum adjuvant were evaluated in a mouse model of SARS, a VLP vaccine, the vaccine given to ferrets and NHP, another whole virus vaccine and an rDNA-produced S protein. Balb/c or C57BL/6 mice were vaccinated IM on day 0 and 28 and sacrificed for serum antibody measurements or challenged with live virus on day 56. On day 58, challenged mice were sacrificed and lungs obtained for virus and histopathology.\nResults\nAll vaccines induced serum neutralizing antibody with increasing dosages and/or alum significantly increasing responses. Significant reductions of SARS-CoV two days after challenge was seen for all vaccines and prior live SARS-CoV. All mice exhibited histopathologic changes in lungs two days after challenge including all animals vaccinated (Balb/C and C57BL/6) or given live virus, influenza vaccine, or PBS suggesting infection occurred in all. Histopathology seen in animals given one of the SARS-CoV vaccines was uniformly a Th2-type immunopathology with prominent eosinophil infiltration, confirmed with special eosinophil stains. The pathologic changes seen in all control groups lacked the eosinophil prominence.\nConclusions\nThese SARS-CoV vaccines all induced antibody and protection against infection with SARS-CoV. However, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components was induced. Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated.\nTranslation: the not-vaccines successfully reduced symptoms and increased antibodies, just as the Covid not-vaccine has. The problem is that they also made the subjects hypersensitive to future SARS infections, which would explain the anomalous Israeli results and suggests that a considerably more lethal pandemic is in the cards.",
  "tags": [
    "healthcare"
  ],
  "categories": [],
  "sitemap_lastmod": "2021-03-25T17:22:55+00:00"
}